SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-23-073254
Filing Date
2023-09-01
Accepted
2023-09-01 16:30:27
Documents
73
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea183928-6k_enlivex.htm   iXBRL 6-K 16095
2 UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR ENLIVEX AS OF JUNE 30, ea183928ex99-1_enlivex.htm   iXBRL EX-99.1 473225
3 OPERATING AND FINANCIAL REVIEW AND PROSPECTS AS OF AND FOR THE THREE AND SIX MON ea183928ex99-2_enlivex.htm EX-99.2 69304
  Complete submission text file 0001213900-23-073254.txt   3928603

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE enth-20230630.xsd EX-101.SCH 57109
5 XBRL CALCULATION FILE enth-20230630_cal.xml EX-101.CAL 27973
6 XBRL DEFINITION FILE enth-20230630_def.xml EX-101.DEF 191406
7 XBRL LABEL FILE enth-20230630_lab.xml EX-101.LAB 393236
8 XBRL PRESENTATION FILE enth-20230630_pre.xml EX-101.PRE 205037
67 EXTRACTED XBRL INSTANCE DOCUMENT ea183928-6k_enlivex_htm.xml XML 515846
Mailing Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042
Business Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042 972 (0) 3 7326616
Enlivex Therapeutics Ltd. (Filer) CIK: 0001596812 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36578 | Film No.: 231232970
SIC: 2834 Pharmaceutical Preparations